New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
09:02 EDTARWRArrowHead Research to publish data of ARC-520 study
Arrowhead Research announced the publication of data demonstrating multi-log reductions in hepatitis B viral DNA and proteins lasting over 30 days after a single injection in animal models. This suggests that Arrowhead's RNAi-based candidate ARC-520 has the potential to treat chronic hepatitis B virus infection in a fundamentally different manner, with the goal of achieving a functional cure. The paper, entitled "Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection," by Wooddell et al, was published online ahead of print in the journal Molecular Therapy. In the publication, Arrowhead scientists describe the use of a novel Dynamic PolyConjugate technology to deliver small interfering RNAs designed against the hepatitis B virus.
News For ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
07:31 EDTARWRArrowhead management to meet with Deutsche Bank
Subscribe for More Information
October 23, 2014
07:44 EDTARWRArrowhead management to meet with Deutsche Bank
Meetings to be held in Minneapolis/Chicago on October 23 hosted by Deutsche Bank.
October 15, 2014
09:57 EDTARWRLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:06 EDTARWRArrowhead pullback since ARC-520 data an overreaction, says Piper Jaffray
Subscribe for More Information
October 14, 2014
14:54 EDTARWRQVT Financial raises passive stake in Arrowhead to 7.62% from 5.29%
Subscribe for More Information
October 13, 2014
07:12 EDTARWROligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
October 10, 2014
12:11 EDTARWROptions with increasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use